home > ict > spring 2020 > a digital approach to enrolment
International Clinical Trials

A Digital Approach to Enrolment

ICT: What is the current market need for greater patient recruitment strategies?

Barbara and Nathalie: Recruitment of patients and healthy volunteers for clinical trials is a well-known bottleneck. The success and timelines for attracting and enrolling patients have a direct impact on the time it takes to get a drug or medical device to the market. Delays result in higher operating costs, losses in sales, and many other drawbacks. In recent years, there has been increasing demand for specialised patient recruitment services in Europe. Approaches that apply for US-based clinical trials cannot be copied ‘as is’ for clinical trials in Europe.

In Europe, it is challenging to navigate through the complex regulatory landscape. There are few or no rules and only minimal guidelines with respect to patient recruitment strategies. Additionally, substantial cultural differences across countries require country-specific recruitment approaches and a high degree of customisation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the authors

Barbara D’haene brings to the company over 10 years of experience in innovation management. In 2015, she was one of the founders of the patient management company Akcelis, which was acquired by Pivotal early 2020. Together with Nathalie Niclaus, she developed innovative patient-centric solutions.

As Co-Founder of Akcelis, Nathalie Niclaus designed and implemented practical solutions to overcome some of the hurdles in clinical trials. She combined all her experience and knowledge of clinical trials to develop innovative solutions and strategies for successful clinical trial patient recruitment and retention.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement